Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …

Recent phase II trials have shown that BRAF/MEK inhibitors and immune checkpoint
inhibitors are active in patients with melanoma brain metastases (MBM), reporting …

Metastatic disease to the brain is a frequent manifestation of melanoma and is associated
with significant morbidity and mortality and poor prognosis. Surgery and stereotactic …

Highlights•For asymptomatic MBM, intracranial response and survival high with
ipilimumab/nivolumab and may be possible to omit radiation in select patients.•For …

Opinion statement Melanoma has a high propensity to metastasize to the brain which
portends a poorer prognosis. With advanced radiation techniques and targeted therapies …

Melanoma is the malignancy with the highest rate of dissemination to the central nervous
system once it metastasizes. Until recently, the prognosis of patients with melanoma brain …

The high rate of brain metastasis in patients with advanced melanoma has been a clinical
challenge for oncologists. Despite considerable progress made in the management of …

Brain metastases from melanoma are no longer uniformly associated with dismal outcomes.
Impressive tumor tissue-based (craniotomy) translational research has consistently shown …

Disseminated metastatic disease, including brain metastases, is commonly encountered in
malignant melanoma. The classical treatment approach for melanoma brain metastases has …

This review aims to provide an overview of nonsurgical treatment strategies for central
nervous system metastases in melanoma as well as discuss treatment challenges and future …